Astrid J F Thielen1, Iris M van Baarsen1, Marlieke L Jongsma1, Sacha Zeerleder2, Robbert M Spaapen1, Diana Wouters3. 1. Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 2. Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, Meibegdreef 9, 1105 AZ Amsterdam, The Netherlands. 3. Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: d.wouters@sanquin.nl.
Abstract
BACKGROUND: To prevent unwanted complement activation and subsequent damage, complement activation must be tightly regulated on healthy host cells. Dysregulation of the complement system contributes to the pathology of diseases like Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome. To investigate complement regulator deficiencies, primary patient cells may be used, but access to patient cells may be limited and cells are heterogeneous between different patients. To inhibit regulator function on healthy host cells, blocking antibodies can be used, though it may be difficult to exclude antibody-mediated effects. To circumvent these issues, we created single and combined complement regulator human knockout cells to be able to in vitro investigate complement activation and regulation on human cells. METHODS: CRISPR/Cas9 was used to knockout (KO) complement regulatory proteins CD46, CD55 and/or CD59 in human HAP1 cells. Single cell derived cell lines were profiled by Sanger sequencing and flow cytometry. To confirm the lack of complement regulatory function, the cells were exposed to complement in normal human serum and subsequently C3 and C4 deposition on the cell surface were detected by using flow cytometry. RESULTS: We created single KO cell lines that completely lacked CD46, CD55 or CD59. We additionally generated double CD46/CD55, CD46/CD59 and CD55/CD59 KOs and triple CD46/CD55/CD59 KOs. Upon classical pathway activation, deletion of CD46 resulted in increased C3 and C4 deposition, while deleting CD55 mainly resulted to increased C3 deposition, confirming their reported function in complement regulation. Upon alternative pathway activation, C3 deposition was only observed on the triple CD46/CD55/CD59 KO cells and not on any of the other cell lines, suggesting that human cells are resistant to spontaneous complement activation and suggesting a role for CD59 in C3 regulation. CONCLUSIONS: The generation of complement regulator KO cell lines provides a relevant tool for future in vitro investigations of complement activation and regulation on human cells. Furthermore, these cell lines may also be helpful to evaluate therapeutic complement inhibitors and may shed light on novel roles of complement regulatory proteins as we here observed for CD59.
BACKGROUND: To prevent unwanted complement activation and subsequent damage, complement activation must be tightly regulated on healthy host cells. Dysregulation of the complement system contributes to the pathology of diseases like Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome. To investigate complement regulator deficiencies, primary patient cells may be used, but access to patient cells may be limited and cells are heterogeneous between different patients. To inhibit regulator function on healthy host cells, blocking antibodies can be used, though it may be difficult to exclude antibody-mediated effects. To circumvent these issues, we created single and combined complement regulator human knockout cells to be able to in vitro investigate complement activation and regulation on human cells. METHODS: CRISPR/Cas9 was used to knockout (KO) complement regulatory proteins CD46, CD55 and/or CD59 in human HAP1 cells. Single cell derived cell lines were profiled by Sanger sequencing and flow cytometry. To confirm the lack of complement regulatory function, the cells were exposed to complement in normal human serum and subsequently C3 and C4 deposition on the cell surface were detected by using flow cytometry. RESULTS: We created single KO cell lines that completely lacked CD46, CD55 or CD59. We additionally generated double CD46/CD55, CD46/CD59 and CD55/CD59 KOs and triple CD46/CD55/CD59 KOs. Upon classical pathway activation, deletion of CD46 resulted in increased C3 and C4 deposition, while deleting CD55 mainly resulted to increased C3 deposition, confirming their reported function in complement regulation. Upon alternative pathway activation, C3 deposition was only observed on the triple CD46/CD55/CD59 KO cells and not on any of the other cell lines, suggesting that human cells are resistant to spontaneous complement activation and suggesting a role for CD59 in C3 regulation. CONCLUSIONS: The generation of complement regulator KO cell lines provides a relevant tool for future in vitro investigations of complement activation and regulation on human cells. Furthermore, these cell lines may also be helpful to evaluate therapeutic complement inhibitors and may shed light on novel roles of complement regulatory proteins as we here observed for CD59.
Authors: Abeer H Obaid; Chryssa Zografou; Douangsone D Vadysirisack; Bailey Munro-Sheldon; Miriam L Fichtner; Bhaskar Roy; William M Philbrick; Jeffrey L Bennett; Richard J Nowak; Kevin C O'Connor Journal: Neurol Neuroimmunol Neuroinflamm Date: 2022-04-26
Authors: Caroline Gavin; Stephan Meinke; Nina Heldring; Kathleen Anne Heck; Adnane Achour; Ellen Iacobaeus; Petter Höglund; Katarina Le Blanc; Nadir Kadri Journal: Front Immunol Date: 2019-09-20 Impact factor: 7.561
Authors: Matthias Wieser; Teresa Francisci; Daniel Lackner; Tilmann Buerckstuemmer; Kamilla Wasner; Wolf Eilenberg; Anton Stift; Markus Wahrmann; Georg A Böhmig; Johannes Grillari; Regina Grillari-Voglauer Journal: PLoS One Date: 2019-04-08 Impact factor: 3.240
Authors: Aleksandra Urban; Daria Kowalska; Grzegorz Stasiłojć; Alicja Kuźniewska; Anna Skrobińska; Emilia Arjona; Eugenia Castellote Alonso; María Ángeles Fenollosa Segarra; Ilse Jongerius; Robbert Spaapen; Simon Satchell; Marcel Thiel; Stanisław Ołdziej; Santiago Rodriguez de Córdoba; Marcin Okrój Journal: Front Immunol Date: 2021-11-25 Impact factor: 7.561
Authors: Dani Ac Heesterbeek; Bart W Bardoel; Edward S Parsons; Isabel Bennett; Maartje Ruyken; Dennis J Doorduijn; Ronald D Gorham; Evelien Tm Berends; Alice Lb Pyne; Bart W Hoogenboom; Suzan Hm Rooijakkers Journal: EMBO J Date: 2019-01-14 Impact factor: 11.598